Stockreport

Urovant Sciences Initiates Phase 3 Clinical Program with Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia

UROVANT SCIENCES LTD COMMON  (UROV) 
Last urovant sciences ltd common earnings: 2/13 04:15 pm Check Earnings Report
PDF IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company developing and commercia [Read more]